At what dose of paracetamol (acetaminophen) poisoning should N‑acetylcysteine be started?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

N-Acetylcysteine Initiation in Paracetamol Poisoning

N-acetylcysteine (NAC) should be started when the serum paracetamol concentration, measured 4-24 hours post-ingestion, plots at or above the "possible toxicity" line on the Rumack-Matthew nomogram—not based on ingested dose alone. 1

Risk Stratification Using the Rumack-Matthew Nomogram

The decision to initiate NAC is not determined by the absolute dose ingested, but rather by plotting the serum paracetamol concentration against time on the Rumack-Matthew nomogram 2:

Key Nomogram Principles:

  • Obtain serum paracetamol concentration at least 4 hours post-ingestion (earlier levels are unreliable as they may not reflect peak concentrations) 1
  • Plot the concentration on the nomogram between 4-24 hours post-ingestion
  • The nomogram has two lines:
    • "Probable toxicity" line (original line)
    • "Possible toxicity" line (25% below the probable line, added by FDA to account for assay errors) 2

Treatment Decision Algorithm:

If concentration is AT OR ABOVE the "possible toxicity" line:

  • Administer NAC loading dose immediately 1
  • This applies to both "possible risk" and "probable risk" zones 2

If concentration is BELOW the "possible toxicity" line:

  • Do NOT administer NAC (minimal hepatotoxicity risk) 2, 1

Critical Timing Considerations

NAC should ideally be initiated within 8-10 hours post-ingestion to maximize hepatoprotection 2. The evidence is compelling:

  • Treatment <8 hours: No severe hepatotoxicity occurred 2
  • Treatment 8-10 hours: Only 1 patient developed non-lethal hepatotoxicity 2
  • Treatment >10 hours: 53% developed severe hepatotoxicity with 5% mortality 2
  • Treatment delay >16 hours: Hepatotoxicity rates reached 62% 2

Special Circumstances Requiring Immediate NAC

Start NAC immediately (before concentration results) in these situations 1:

  1. Unknown time of ingestion
  2. Paracetamol concentration unavailable within 8 hours of ingestion
  3. Clinical evidence of paracetamol toxicity present
  4. Presentation >8 hours post-ingestion (start NAC, then obtain level to guide continuation)
  5. Extended-release formulation (obtain second level at 8-10 hours if first level at 4 hours is below toxicity line)

High-Risk Populations

Consider treating even with "non-toxic" nomogram levels in patients with 1:

  • Chronic alcoholism
  • Malnutrition
  • CYP2E1 enzyme-inducing drugs (e.g., isoniazid)

The nomogram may underestimate hepatotoxicity risk in these populations.

Situations Where the Nomogram Cannot Be Used

For patients who cannot be risk-stratified by the nomogram, use clinical judgment and laboratory markers 2:

Administer NAC if:

  • Hepatic failure thought to be due to paracetamol 2
  • Hepatotoxicity present (elevated transaminases) with suspected paracetamol overdose 2
  • Repeated supratherapeutic ingestion (>4g/24h or >200mg/kg in 24h, or >6g or >150mg/kg per 24h for ≥48 hours) 2
  • Presentation >24 hours post-ingestion with detectable paracetamol or elevated transaminases 2

Common Pitfalls to Avoid

  1. Do not rely on reported ingested dose alone to make treatment decisions—the history is often inaccurate 1
  2. Do not obtain paracetamol levels <4 hours post-ingestion—they are misleading 1
  3. Do not delay NAC if presentation is >8 hours post-ingestion—start immediately while awaiting levels 1
  4. Do not withhold NAC after 24 hours—it still provides benefit in established hepatotoxicity and hepatic failure 2

Evidence Strength

The FDA drug label 1 and ACEP guidelines 2 provide Level B recommendations (moderate clinical certainty) that NAC should be administered to patients with possible or probable risk by nomogram, ideally within 8-10 hours. The evidence consistently demonstrates that timing matters more than absolute dose, with dramatic increases in hepatotoxicity when treatment is delayed beyond 10 hours 2.

While research suggests reported doses >30-34g have a 50% probability of requiring NAC 3, this should not replace nomogram-based decision-making in acute presentations where serum levels can be obtained.

References

Related Questions

In a patient who ingested 8,500 mg acetaminophen over 20 hours, weighs 85 kg, and has normal liver function tests, should N‑acetylcysteine be started in the emergency department?
What is the recommended intravenous N‑acetylcysteine (NAC) regimen for a 50‑kg patient with paracetamol (acetaminophen) poisoning?
How is intravenous N‑acetylcysteine (NAC) prepared for the two‑bag (20‑hour) regimen?
What is the recommended N‑acetylcysteine dosing regimen for acetaminophen (paracetamol) overdose in adults and children?
When to initiate treatment for elevated acetaminophen (paracetamol) levels?
In a patient with primary adrenal insufficiency whose other signs have improved but who still has persistent muscle cramps and markedly elevated ACTH and elevated plasma renin activity, what is the appropriate management?
What is the appropriate management of hypernatremia?
What is the appropriate treatment for cystic acne of the nostril?
In an adult patient with chronic deep‑vein thrombosis who has persistent pain, swelling, or signs of post‑thrombotic syndrome despite adequate anticoagulation, what interventional radiology (IR) approach is recommended?
What blood glucose level defines hypoglycemia?
What is the recommended evaluation and management for a patient who, after head trauma, has mild gait imbalance, impaired smooth pursuit eye movements, and weak tandem gait?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.